| Just Other Articles |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Finance > Finance > The Environment of the EU Banking System |
|
Just Other Articles - The Environment of the EU Banking System
Banks are defined as a business organisation that performs services in relation to money. Specifically is the process of keeping money for customers and paying it out on demand, in the form of de According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product posits, borrowings and exchanges. It has become a clich? to note the revolutionary impact of information technology (IT) upon any industry, but the real upheaval lies just ahead. As experts back ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in n the 90s stated, "If the number-crunching mainframe computers of the 1970s formed the childhood of IT, and the flowering of personal computers during the 1980s marked its youthful adolescence, t lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. en the 1990s seem likely to see the passage of IT into adulthood". As it has been foreseen, during the 21st Century, technology became directly related to almost every single activity and functio here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe of a bank. Deposits, withdrawals, loans, transfer of capital and updating are just some of the functions that are carried out electronically, as computers support communication networks or ATMs. d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro In the late 1990s, banks have come to realise even more and understand better the importance of technology since they have tried to take advantage of its progress. The computer sciences and all ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc spects in telecommunications, with particular emphasis on the Internet capabilities, constituted one of the most profitable areas banks decided to invest. These two fields of technology have had easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi he greatest potential for growth and profitability. Currently, as the banks anticipate the rapid IT growth potentials, they continue to give a lot of emphasis on the technology of e-banking-the t nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically ansactions with banks through Internet-and e-commerce of products and services. Noticeable is the fact that almost every bank in the globe currently offers e-banking services via their Internet l and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ nks. During the past ten years, a trend has emerged as major banks or groups of banks have formed alliances with companies in the telecommunications and computer sciences fields, or in other div ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi rse industries. For example, in the UK, two Scottish banks have joined up with major supermarket chains in order to provide an outsourced banking function for the so-called supermarket banks. The ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a motive for such kind of strategic decisions was the profit from a dynamic field that showed revenues increasing in a rapid rate. Furthermore, it is true that the Banking Sector throughout Europe dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod has gradually restructured itself in order to be able to meet the challenges provoked by the unification that has recently reached the milestone of twenty-five member states. Operating in this ne cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin environment, banks have to confront some major issues, such as the intensification of competition, the technology breakthroughs referring to transactions, the globalisation of capital and money tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen arkets, the development of management and administration, the extensive use of derivatives, the development of international transactions and the introduction of financial innovations. Thus, EU b t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel nks in order to cope with the fundamental forces mentioned above, are trying to find ways to improve their productivity and effectiveness, reduce their costs, upgrade the quality of the services ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust hey provide, intensify their presence in new markets, reduce the exchange risk, and finally achieve great macroeconomic stability. Experts state that the upcoming changes will also force banks t y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products reconsider their position in terms of effective bank size, economies of scale in the new environment, creation of a new powerful capital base, globalisation of the activities as well as of the w . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de de variety of product/service lines they provide to customers. According to the estimations of "International Monetary Fund" and the "Organisation for Economic Co-operation and Development", it i elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip a fact that the banks have already invested significant capitals to new technology applications, while most have already introduced "personalized" services for their European or global customers tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Golf Fundraiser For NonProfit Groups Information as a Competitive Advantage – Part 8, Risk Mitigation Fees -- Is It Time to Reconsider Yours?
|